您当前的位置：
首页 >
文章列表页 >
Regulatory policy analysis of pharmacy compounding drug products in the United States and its implications
更新时间：2026-07-28

    • Regulatory policy analysis of pharmacy compounding drug products in the United States and its implications

    • ZHONGGUO YAOFANG   Vol. 37, Issue 14, Pages: 1819-1825(2026)

    • DOI：10.6039/j.issn.1001-0408.2026.14.04    

      CLC： R95;R94

    • Received：27 January 2026，

      Revised：2026-06-10，

      Accepted：02 July 2026，

      Online First：24 July 2026，

      Published：30 July 2026

    移动端阅览

  • LI Haijian,DENG Anqi,GUO Qing,et al.Regulatory policy analysis of pharmacy compounding drug products in the United States and its implications[J].ZHONGGUO YAOFANG,2026,37(14):1819-1825. DOI： 10.6039/j.issn.1001-0408.2026.14.04.

  •  
  •  

0

Views

0

下载量

0

CSCD

Alert me when the article has been cited
提交
Tools
Download
Export Citation
Share
Add to favorites
Add to my album

Related Articles

我国公立医院药房改革路径探讨
Mechanism of Yigan huayu formula in alleviating liver fibrosis based on proteomics
Study on the mechanism of Euphorbia hirta L.-derived exosome-like nanovesicles regulating Nrf2/HO-1/NQO1 pathway to improve acetaminophen-induced liver injury
Mechanism of Huangqin decoction in improving ulcerative colitis based on the gut microbiota-tryptophan metabolism-aryl hydrocarbon receptor axis
Study on the effect and mechanism of processed Oxytropis falcata in improving renal fibrosis in rats

Related Author

YANG Yue
ZONG Maomao
YOU Xiaomin
ZHAO Rui
CHAI Qianwen

Related Institution

No data
0